Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18204439 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Yang JY, et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10, 138-48 18204439
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S294-p - FOXO3A (human)
Orthologous residues
FOXO3A (human): S294‑p, FOXO3A (mouse): S293‑p, FOXO3A (rat): S293‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
Downstream Regulation
 Effect of modification (function):  activity, inhibited, molecular association, regulation, protein degradation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MDM2 (human) Induces co-immunoprecipitation
 Comments:  promotes tumorigenicity

S344-p - FOXO3A (human)
Orthologous residues
FOXO3A (human): S344‑p, FOXO3A (mouse): S343‑p, FOXO3A (rat): S343‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
Downstream Regulation
 Effect of modification (function):  activity, inhibited, molecular association, regulation, protein degradation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MDM2 (human) Induces co-immunoprecipitation
 Comments:  promotes tumorigenicity

S425-p - FOXO3A (human)
Orthologous residues
FOXO3A (human): S425‑p, FOXO3A (mouse): S424‑p, FOXO3A (rat): S424‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease
Downstream Regulation
 Effect of modification (function):  activity, inhibited, molecular association, regulation, protein degradation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MDM2 (human) Induces co-immunoprecipitation
 Comments:  promotes tumorigenicity


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.